Bone Metastasis Model Development in an Immunocompetent Murine Host - - PowerPoint PPT Presentation

bone metastasis model development in an immunocompetent
SMART_READER_LITE
LIVE PREVIEW

Bone Metastasis Model Development in an Immunocompetent Murine Host - - PowerPoint PPT Presentation

Bone Metastasis Model Development in an Immunocompetent Murine Host December 9, 2017 Alexander H. Jinnah MD, Daniel N. Bracey MD PhD, Thomas L. Smith PhD, Bethany A. Kerr PhD Background Prevalence of bone metastasis is 280,000 in US


slide-1
SLIDE 1

Bone Metastasis Model Development in an Immunocompetent Murine Host

Alexander H. Jinnah MD, Daniel N. Bracey MD PhD, Thomas L. Smith PhD, Bethany A. Kerr PhD

December 9, 2017

slide-2
SLIDE 2

Wake Forest Baptist Medical Center

  • Prevalence of bone metastasis is 280,000 in US
  • Serious skeletal complications
  • Hypercalcemia, spinal cord compression, bone pain, pathological

fractures

  • Survival after bone metastasis diagnosis is ~ 2 years

2

Background

Li et al. 2012 Thibaudeau et al. 2014 Holen et al. 2015

slide-3
SLIDE 3

Wake Forest Baptist Medical Center 3

  • Treatment strategies consist of:
  • Chemotherapy
  • Immunotherapy
  • Radiopharmaceuticals
  • Bisphosphonates
  • Surgery

Background

Will not cure – will

  • nly treat symptoms
slide-4
SLIDE 4

Wake Forest Baptist Medical Center 4

?

Lack of an appropriate in vivo models Current Models:

1. Direct injection 2. Intracardiac Injection

slide-5
SLIDE 5

Wake Forest Baptist Medical Center

Purpose

To create an in vivo bone metastasis model in an immunocompetent host using a decellularized porcine xenograft

5

slide-6
SLIDE 6

Wake Forest Baptist Medical Center

Methods

  • Decellularized xenograft was created using

porcine femurs

6

slide-7
SLIDE 7

Wake Forest Baptist Medical Center

Methods

  • To determine osteoblast viability and osteoinductive

potential - Pre-osteoblasts were seeded on the scaffold

  • Incubated for 1 week with and without ascorbic acid
  • Analyzed for gene expression (qPCR) of Alkaline Phosphatase

and BMP-7

7

Cells + Ascorbic Acid Cells No Ascorbic Acid Scaffold + Ascorbic Acid Scaffold No Ascorbic Acid

slide-8
SLIDE 8

Wake Forest Baptist Medical Center

Methods

  • To determine prostate Ca viability on scaffold – prostate

cancer cells were seeded on the scaffold

  • Incubated for 1 week
  • Analyzed for gene expression (qPCR) of mTor, SOX-2 and

RANKL

8

Prostate Ca Cells Scaffold + Prostate Ca. Cells

slide-9
SLIDE 9

Wake Forest Baptist Medical Center

Methods

  • To determine osteoblast viability and osteoinductive

potential in vivo

  • Pre-osteoblasts seeded scaffolds and unseeded scaffolds were

implanted subcutaneously on the dorsum of a mouse

  • Explanted scaffolds were analyzed for gene expression (qPCR) of

Wnt3a, BMP-2, and OSX

  • 5 seeded and 5 unseeded were microCT scanned
  • Histological and Immunohistochemistry Analysis

9

slide-10
SLIDE 10

Wake Forest Baptist Medical Center

Results

slide-11
SLIDE 11

Wake Forest Baptist Medical Center 11

  • Increased Alkaline phosphatase expression in scaffold
  • Ascorbic acid lead to further increase in expression
  • No significant differences seen in BMP-7

Pre-osteoblasts In-vitro

BMP-7

Scaffold Monolayer 2 4 6 8 10 40 80

Control + Ascorbic

Gene Expression Relative to control Normalized to 18S

Alkaline Phosphatase BMP-7

slide-12
SLIDE 12

Wake Forest Baptist Medical Center 12

Cancer Cells In-Vitro

  • mTor and sox-2 gene expression were significantly higher in the scaffold

than the control monolayer

  • Suggests cancer cell proliferation
slide-13
SLIDE 13

Wake Forest Baptist Medical Center 13

In-Vitro

  • RANKL gene expression was

significantly higher in the scaffold than the control monolayer

  • Suggests osteoblast activity

Cancer Cells In-Vitro

slide-14
SLIDE 14

Wake Forest Baptist Medical Center

  • gene expression was

significantly greater in all groups

14

Pre-osteoblasts In-vivo

BMP-2

k 2 4 6 8 10 100 200

cells No cells

*

Gene Expression Relative to control Normalized to 18S

wnt3a

1 2 3 4 5 1000 2000

cells No cells

*

Gene Expression Relative to control Normalized to 18S

slide-15
SLIDE 15

Wake Forest Baptist Medical Center 15

Pre-osteoblasts In-vivo

  • MicroCT Scans were performed on 8 of 10 scaffolds

due to inadequate pre-implantation scans

  • 2 more were excluded based on inadequate post-

implantation scan or partial destruction of the scaffold

  • Increase in bone volume and trabecular thickness post-

implantation (ns)

Trabecular Thickness

Scaffold Scaffold + OB 1 2 3 4 5

Pre Implantation Post Implantation Average Tb.Th Fold change

slide-16
SLIDE 16

Wake Forest Baptist Medical Center 16

Histological Analysis

  • H&E staining demonstrating cellular material accumulating within the scaffold
  • IHC staining demonstrated that these cells express osteopontin
  • Pentachrome staining demonstrating new collagen formation within the pores
slide-17
SLIDE 17

Wake Forest Baptist Medical Center

Conclusions

slide-18
SLIDE 18

Wake Forest Baptist Medical Center 18

Conclusions

  • Osteoinductive potential of decellularized porcine

xenograft

  • Decellularized xengoraft is a viable host to osteoblasts

in vivo and in vitro and to cancer cells in vitro

  • Implant scaffold and a tumor into immunocompetent

mouse

  • PET-CT

Future Work

slide-19
SLIDE 19

Wake Forest Baptist Medical Center 19